Article - 29/01/2019 Targeted RNA editing with the body’s own enzyme activity Completely new possibilities for research and gene therapy became available following the development of the CRISPR/Cas method for targeted modification of the genome. However, treatment with molecular scissors is not without risk as potential errors are stored in the genome forever. Scientists from Tübingen have developed an alternative method in which the intervention takes place at the RNA level using the body's own enzymes and is thus…https://www.gesundheitsindustrie-bw.de/en/article/news/targeted-rna-editing-with-the-bodys-own-enzyme-activity
Press release - 28/01/2019 5,5 millions for project on smart matrices for knee cartilage repair A research project in cartilage regeneration, in which the Institute of Orthopaedic Research and Biomechanics at Ulm University participates together with partners from eight european countries, was recently financed by the European Commission with 5.5 million Euro. Named RESTORE, the project aims to create 3D matrices incorporating smart nanomaterials to repair knee cartilage lesions thereby reducing or delaying the onset of osteoarthritis,…https://www.gesundheitsindustrie-bw.de/en/article/press-release/55-millions-for-project-on-smart-matrices-for-knee-cartilage-repair
Article - 24/01/2019 Scientists to combat antibiotic-resistant bacteria in wastewater In Germany, around 1,500 tonnes of antibiotics per year are administered to humans and animals. As a result, more and more bacteria are developing resistance to common antibiotics. As part of HyReKA, a cooperative project funded by the BMBF, scientists led by Professor Thomas Schwartz from the KIT are investigating how antibiotic-resistant pathogens spread and how they can be prevented from doing so.https://www.gesundheitsindustrie-bw.de/en/article/news/scientists-to-combat-antibiotic-resistant-bacteria-in-wastewater
Expert interview - 16/01/2019 Cybersecurity is an important issue for the pharmaceutical industry In an increasingly interconnected world, the pharmaceutical and biotechnology sectors need to be aware of cybersecurity threats in manufacturing. We talked about these threats with Holger Mettler who is in charge of computer system validation and cybersecurity at Exyte (formerly M + W), a global enterprise that designs, engineers and constructs complex manufacturing facilities and buildings for the life sciences industry.https://www.gesundheitsindustrie-bw.de/en/article/news/cybersecurity-is-an-important-issue-for-the-pharmaceutical-industry
Article - 10/01/2019 Stocktaking and recommendations for action: the BBAW’s fourth gene technology report In the new gene technology report, the interdisciplinary working group of the Berlin-Brandenburg Academy of Sciences (BBAW) takes stock of gene technology developments in Germany during the past few decades, and discusses the societal, legal and ethical challenges associated with these technologies in the future. The report is highly topical due to the controversy surrounding the ruling of the European Court of Justice on CRISPR/Cas9 genome…https://www.gesundheitsindustrie-bw.de/en/article/news/stocktaking-and-recommendations-for-action-the-bbaws-fourth-gene-technology-report
Company profile - 09/01/2019 HQS Quantum Simulations for industrial quantum mechanics applications The door to the quantum world is opening wider and wider. Behind it is a whole new view of materials and molecules. Quantum mechanics applications not only benefit science, they also offer huge economic potential. The Karlsruhe start-up HQS Quantum Simulations is playing a pioneering role in quantum simulations for the chemical and pharmaceutical industries.https://www.gesundheitsindustrie-bw.de/en/article/news/hqs-quantum-simulations-for-industrial-quantum-mechanics-applications
Company profile - 19/12/2018 With DiHeSys into integrated digital healthcare The founders and partners of DiHeSys have big ambitions: "We have to build a complete ecosystem around the patient," says Dr. Markus Dachtler, managing director of DiHeSys. The company develops products and services for an industry in transition, provides answers to trends such as personalized medicine, 2D- and 3D-printing technologies and platform technologies. The company’s motto: no isolated solutions, but a comprehensive range of…https://www.gesundheitsindustrie-bw.de/en/article/news/with-dihesys-into-integrated-digital-healthcare
Anniversary - 12/12/2018 15 years of BIOPRO: Pooling competencies – pushing innovations This is the leitmotif of BIOPRO Baden-Württemberg GmbH, which was founded in 2003. 15 years is a good time to pause for a moment and take a look at BIOPRO’s work and achievements. As a central point of contact and wholly-owned subsidiary of the Baden-Württemberg government whose main objective is to promote networking, BIOPRO knows only too well that progress is not made alone, but in collaboration with others.https://www.gesundheitsindustrie-bw.de/en/article/press-release/15-years-of-biopro-pooling-competencies-pushing-innovations
Press release - 10/12/2018 High distinction for stem cell researcher Andreas Trumpp This year's State Research Prize of Baden-Württemberg awarded for outstanding achievements in applied research goes to Andreas Trumpp from the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM). Theresia Bauer, State Minister of Science, Research and the Arts, presented the award, which carries a monetary prize of €100.000, at a festive ceremony on December 10, 2018.https://www.gesundheitsindustrie-bw.de/en/article/press-release/high-distinction-for-stem-cell-researcher-andreas-trumpp
Press release - 03/12/2018 SpinDiag closes second financing round of EUR 3.0 million (USD 3.4 million) to complete product development of its point-of-care screening system for antibiotic-resistant bacteria One year after its seed financing, SpinDiag GmbH closes a second financing round of EUR 3 million (USD 3.4 million) as planned. The financing will enable SpinDiag to complete the product development of its first product for screening for antibiotic-resistant bacteria and to start clinical trials. This will pave the way for regulatory approval in the EU.https://www.gesundheitsindustrie-bw.de/en/article/press-release/spindiag-closes-second-financing-round-of-eur-30-million-usd-34-million-to-complete-product-development-of-its-point-of-care-scr
Press release - 29/11/2018 Hattrick in Freiburg Three researchers at the MPI for Immunobiology and Epigenetics receive millions in funding from the European Research Council. Dominic Grün, Nicola Iovino and Ritwick Sawarkar from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg will each be awareded one of the prestigious Consolidator Grants of the European Research Council. This means that 6 million euros in funding will go to fundamental research in Freiburg over the next…https://www.gesundheitsindustrie-bw.de/en/article/press-release/hattrick-in-freiburg
Plant breeding - 19/11/2018 Tobacco for health Plants can be used as biofactories to produce valuable active ingredients such as proteins, antibodies, dyes or vaccines. A project called Newcotiana aims to re-position the existent tobacco industry infrastructure. The project partners, including Prof. Dr. Holger Puchta from the Karlsruhe Institute of Technology, use modern breeding methods to develop tobacco varieties with new capabilities.https://www.gesundheitsindustrie-bw.de/en/article/news/tobacco-for-health
Company profile - 19/11/2018 CHILI GmbH – teleradiology pioneers Teleradiology is the most advanced telemedicine application in Germany. CHILI GmbH from Dossenheim is one of the companies that has contributed to driving the development of teleradiology forward. The company specialises in PACS and teleradiology systems and helps connect clinics and physicians.https://www.gesundheitsindustrie-bw.de/en/article/news/chili-gmbh-teleradiology-pioneers
Biosensor - 13/11/2018 Rapid medical test for at-home use For quite a number of illnesses, patients need to have the concentrations of the medications they are taking and their blood metabolites checked on a regular basis, which can make life rather difficult. Researchers at the Max Planck Institute for Medical Research in Heidelberg have now developed a test based on the firefly enzyme luciferase. This enzyme can be used to quickly and cheaply measure parameters of interest.https://www.gesundheitsindustrie-bw.de/en/article/news/rapid-medical-test-for-at-home-use
Article - 30/10/2018 Eucor – bringing the European Campus to life Enrolling at one university and being able to use the services of a total of five universities is unique in the European Research Area. A model project called Eucor - The European Campus offers students and young scientists this opportunity at universities in the Germany-France-Switzerland border triangle, which simultaneously acts as a borderless academic area for the sciences. https://www.gesundheitsindustrie-bw.de/en/article/news/eucor-bringing-the-european-campus-to-life
Article - 29/10/2018 Aminolipine: formaldehyde-free substitute for preserving biological tissues For almost 125 years, undertakers as well as physicians in the fields of anatomy and pathology have used formaldehyde to preserve biological tissue and whole cadavers. Yet, formaldehyde is highly toxic and linked to cancer. A team led by Prof. Dr. Bernhard Hirt from the Institute of Clinical Anatomy and Cell Analysis at the University Hospital in Tübingen has developed a formaldehyde-free replacement substance.https://www.gesundheitsindustrie-bw.de/en/article/news/aminolipine-formaldehyde-free-substitute-for-preserving-biological-tissues
Expert interview - 17/10/2018 Biologicals are becoming increasingly important to Boehringer Ingelheim Biopharmaceuticals are playing an increasingly important role in Boehringer Ingelheim’s development pipeline. Visible evidence of this is the company’s Biologicals Development Centre (BDC) that is currently being constructed in Boehringer Ingelheim’s Biberach plant and will bring the company’s process development under one roof by early 2020. Walter Pytlik from BIOPRO talked with Dr. Ing. Ralf Schumacher about the new centre.https://www.gesundheitsindustrie-bw.de/en/article/news/biologicals-are-becoming-increasingly-important-to-boehringer-ingelheim
Article - 10/10/2018 BABYBE GmbH: Premature babies in contact with mum around the clock It used to be believed that premature babies needed as much rest as possible. However, studies have since shown that this is not the case at all. According to these studies, the brains of premature babies need to be stimulated 24 hours a day, ideally close to the mother, to ensure healthy development. The Stuttgart-based start-up BABYBE GmbH has developed a special gel mattress that enables babies to perceive their mother’s heartbeat and voice…https://www.gesundheitsindustrie-bw.de/en/article/news/babybe-gmbh-premature-babies-in-contact-with-mum-around-the-clock
Article - 02/10/2018 Artificial intelligence in the life sciences: machines as assistants Artificial intelligence is currently one of the most innovative issues, but also one of the most controversial research areas. It already has a firm footing in many areas of our everyday life and often we are not even aware of it. Artificial intelligence has long been an integral part of many processes in research and diagnostics in medicine and the life sciences – and it will be even more widely used in the future.https://www.gesundheitsindustrie-bw.de/en/article/news/artificial-intelligence-in-the-life-sciences-machines-as-assistants
Press release - 27/09/2018 Three new Clusters of Excellence for Tübingen University takes next hurdle in the German government’s Excellence Strategy funding program. The University of Tübingen is to have three new Clusters of Excellence.As part of the German government’s Excellence Strategy funding forhigher education research, Tübingen will host new outstanding research networks starting in January 2019. Representatives of Germany’s higher education policymakers announced the decision in Bonn on Thursday.https://www.gesundheitsindustrie-bw.de/en/article/press-release/three-new-clusters-of-excellence-for-tuebingen
Press release - 27/09/2018 One hundred percent success Two Clusters of Excellence for the University of Freiburg: Biological Signalling Studies and Bioinspired Materials Research. It is a major boost to cutting-edge research in Freiburg: in the current Excellence Strategy competition, scientists at the University of Freiburg have been granted two Clusters of Excellence, CIBSS – Centre for Integrative Biological Signalling Studies, and livMatS – Living, Adaptive and Energy-autonomous Materials…https://www.gesundheitsindustrie-bw.de/en/article/press-release/one-hundred-percent-success
Industry report 2018 - 27/09/2018 The healthcare industry – the innovation driver of the 21st century: opportunities and challenges BIOPRO Baden-Württemberg’s new industry report entitled "The Healthcare Industry 2018: Facts and Figures for Baden-Württemberg" has just been published in both German and English. The topic neatly dovetails with the state’s political activities. An evaluation of the region carried out on behalf of the Baden-Württemberg government has clearly recognised the importance of the healthcare sector as a driver of innovation.https://www.gesundheitsindustrie-bw.de/en/article/press-release/the-healthcare-industry-the-innovation-driver-of-the-21st-century
Cancer immunotherapy - 06/09/2018 The immunogenicity of tumours and the development of new cancer medicines Microsatellite-unstable cancers are characterised by a large number of mutations within short repetitive DNA sequence regions, and can form novel peptides that the human immune system recognises as neoantigens. These cancers represent a starting point for the development of vaccines to prevent them appearing at an early stage of development. Microsatellite instability is particularly frequent in colon and cervical cancers.https://www.gesundheitsindustrie-bw.de/en/article/news/the-immunogenicity-of-tumours-and-the-development-of-new-cancer-medicines
Dossier - 28/08/2018 With molecular diagnostics to biomarker-based personalised therapy Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases.https://www.gesundheitsindustrie-bw.de/en/article/dossier/with-molecular-diagnostics-to-biomarker-based-personalised-therapy
Press release - 27/08/2018 Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager-based Immunotherapeutics for Multiple Cancer Targets Affimed will receive $96 million upfront and committed funding and is eligible for up to an additional $5.0 billion including milestone payments, and royalties on sales.https://www.gesundheitsindustrie-bw.de/en/article/press-release/affimed-announces-collaboration-with-genentech-to-develop-novel-nk-cell-engager-based-immunotherapeutics-for-multiple-cancer-tar